8-K: Atlantic Coastal Acquisition Corp. II Announces Filing of S-4 for Abpro Business Combination

Atlantic Coastal Acquisition Corp. II has filed a registration statement on Form S-4 with the SEC in connection with its proposed business combination with Abpro Corporation.

Summary

• Atlantic Coastal Acquisition Corp. II (ACAB) has announced the filing of a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) on January 19, 2024, related to its proposed business combination with Abpro Corporation.
• The proposed business combination values Abpro at an implied pre-money equity valuation of $500 million.
• Upon closing, the combined company is expected to be named Abpro Corporation and will list its common stock on Nasdaq under the ticker symbol ABP.
• The transaction is expected to close in the first half of 2024, pending approvals from both Atlantic Coastal and Abpro stockholders and other customary closing conditions.
• The transaction is expected to be funded through a combination of a $20 million PIPE financing and an estimated $7.2 million of ACAB cash in trust.
• Abpro shareholders will roll over 100% of their equity, representing approximately 87% of the pro forma equity value.
• Net proceeds from the transaction are intended to fund Abpro's operations in the first half of 2024, including research and development and clinical development of its two lead programs.
• Abpro's lead candidates include ABP-102, a TetraBi antibody for HER2+ solid tumors, and ABP-201, a TetraBi antibody for wet age-related macular degeneration.
• The risk-adjusted present value of future revenue from both assets combined is estimated at approximately $1.2 billion.
• Abpro's two lead assets are expected to peak at approximately $1.6 billion in combined revenue.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for the business combination and Abpro's future prospects, highlighting the company's strong pipeline, strategic partnerships, and experienced management team. The financial projections are also promising, contributing to a high sentiment score.

Positives

• The business combination provides Abpro with access to public markets and additional capital.
• Abpro has a robust pipeline of next-generation antibody therapeutics.
• The company has strategic partnerships with Celltrion and Abpro Bio.
• Abpro's lead candidates target significant unmet medical needs in oncology and ophthalmology.
• The company's proprietary DiversImmune and MultiMab platforms are validated by global pharma and research institutions.
• The management team has extensive biotechnology experience.
• The risk-adjusted present value of future revenue from both assets combined is approximately $1.2 billion.
• Abpro's two lead assets are expected to peak at approximately $1.6 billion in combined revenue.

Negatives

• The transaction is subject to customary closing conditions and approvals, including stockholder approval.
• The company is in the early stages of development, which carries inherent risks.
• The company is dependent on senior management and other key employees.
• There are risks related to regulatory approvals and commercialization of products.
• The company's financial results and business metrics are likely to fluctuate on a quarterly and annual basis.
• Market opportunity estimates and growth forecasts are subject to significant uncertainty.
• There are risks related to the company's ability to retain and expand its development agreements.

Risks

• The business combination may not be completed in a timely manner or at all.
• There is a risk that the combined company may not be able to obtain additional financing.
• The combined company's securities may be volatile and lack liquidity.
• There are risks related to the company's ability to manage growth and execute its business strategy.
• The company faces risks related to regulatory matters, including approvals and compliance.
• There are risks related to the company's intellectual property and potential claims by third parties.
• The company may not be able to raise additional capital or generate the necessary capital to maintain and expand its operations.
• There are risks related to the company's ability to operate as a public company and comply with applicable laws and regulations.
• Certain directors and officers may have interests in the business combination that differ from those of shareholders.
• The company faces risks related to the limited public company experience among its management team.

Future Outlook

The combined company is expected to focus on advancing Abpro's pipeline of next-generation antibody therapeutics, with the goal of bringing critical therapies to market. The company anticipates filing IND applications for ABP-102 and ABP-201 in the first half of 2025 and initiating Phase 1 clinical trials in the second half of 2025.

Management Comments

• Ian Chan, CEO and co-founder of Abpro, stated they are thrilled to be one step closer to fulfilling their public journey to advance their pipeline of next-generation antibody therapeutics.
• Shahraab Ahmad, CEO of Atlantic Coastal, expressed excitement about partnering with Abpro and recognized the potential of the company's drug discovery platform.
• Tony Eisenberg, CSO of Atlantic Coastal, stated he has been most impressed with the caliber of the team at Abpro and has confidence in their ability to achieve their targets.

Industry Context

This announcement reflects the ongoing trend of biotech companies seeking public market access through SPAC mergers. The focus on antibody therapeutics aligns with the growing interest in targeted therapies for cancer and other diseases. The strategic partnerships with Celltrion and Abpro Bio highlight the importance of collaborations in the biotech industry.

Comparison to Industry Standards

• The $500 million pre-money valuation for Abpro is within the range of valuations for early-stage biotech companies with promising pipelines.
• The strategic partnership with Celltrion is similar to other collaborations in the biotech industry where larger companies fund development in exchange for commercial rights.
• The focus on bispecific antibodies aligns with the industry trend towards developing more potent and targeted therapies.
• The estimated $1.2 billion risk-adjusted present value and $1.6 billion peak revenue potential for Abpro's lead assets are ambitious but not uncommon for companies with successful clinical trials.
• The development timelines for ABP-102 and ABP-201, with IND filings expected in 1H 2025 and Phase 1 trials in 2H 2025, are typical for early-stage clinical programs.

Stakeholder Impact

• Shareholders of Atlantic Coastal will have the opportunity to participate in the growth of Abpro.
• Abpro shareholders will retain a significant stake in the combined company.
• Employees of both companies will be impacted by the integration process.
• Patients may benefit from the development of new therapies for severe and life-threatening diseases.
• The transaction may create value for investors in the biotech sector.

Next Steps

• The companies will seek approval from their respective stockholders for the business combination.
• Atlantic Coastal will mail a definitive proxy statement/prospectus to its stockholders.
• Abpro will continue to advance its lead candidates, ABP-102 and ABP-201, towards clinical trials.
• The companies will work towards completing the business combination in the first half of 2024.
• Abpro plans to file IND applications for ABP-102 and ABP-201 in the first half of 2025.
• Abpro plans to initiate Phase 1 clinical trials for ABP-102 and ABP-201 in the second half of 2025.

Key Dates

Keywords

business combination, biotechnology, antibody therapeutics, oncology, ophthalmology, SPAC, Nasdaq, clinical development, HER2, VEGF, ANG-2, T-cell engager, DiversImmune, MultiMab, Celltrion, Abpro Bio